Endoxan Baxter 50 mg Compresse rivestite
Sponsors
Istituto Europeo Di Oncologia S.r.l., European Myeloma Network B.V., Ceska Myelomova Skupina z.s., Emn Trial Office S.r.l. Impresa Sociale, Fondazione IRCCS Istituto Nazionale Dei Tumori
Conditions
Locally recurrentPseudomyxoma peritonei patients with high tumor burden.YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIGIBLE TO THE AUTOLOGOUS TRANSMISSION OF STEM CELLSand/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wallinoperable
Phase 2
A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd) versus the association of bortezomib-thalidomide-dexamethasone (VTd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) young patients eligible for autologous stem cell transplantation
Active, not recruitingCTIS2024-511781-37-00
Start: 2019-04-16Target: 401Updated: 2025-11-26
Combination of pembrolizumab with oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): A phase II study
Active, not recruitingCTIS2023-507365-26-00
Start: 2020-05-20Target: 46Updated: 2024-12-10
Metronomic neoadjuvant capecitabine and cyclophosphamide in huge (PCI>28) Pseudomyxoma peritonei (PMP) patients candidates to cytoreductive surgery (CRS) and hypertermic intraperitoneal chemotherapy (HIPEC).
RecruitingCTIS2024-514329-42-00
Start: 2024-11-22Target: 31Updated: 2025-12-03